On certain days, the hard work is present, but the outcomes are missing
Second, targeting eryptosis pathways offers new therapeutic opportunities: strategies to mitigate eryptosis could include optimizing clearance of eryptosis-inducing uremic toxins via advanced dialysis modalities (e.g., hemodialysis combined with hemadsorption [HA + HD] for protein-bound uremic toxins) or novel pharmacotherapies, such as inhibitors of Organic Anion Transporter 2 (OAT2) to block indoxyl sulfate uptake by erythrocytes, antioxidants (e.g., N-acetyl-L-cysteine, vitamin E) to counteract oxidative stress-mediated eryptosis, or modulators of Ca 2+ signaling (e.g., NO donors) to stabilize erythrocyte membrane asymmetry
Kuah E, Toh S, Yee J et al (2016) Enzyme mimics: advances and applications
Figure 4 SLC7A11 also affects the nutrient dependence of tumor cells through glutamine backfilling and GLS dependence ( SLC7A11 and immune regulation Within the tumor microenvironment, interactions involving SLC7A11 between immune cells and tumor cells play a significant role in influencing tumor survival and proliferation